- Home
- GSRT vs ALDX Comparison
GSRT vs ALDX Comparison
Compare GSRT & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSRT
- ALDX
- Stock Information
- Founded
- GSRT 2023
- ALDX 2004
- Country
- GSRT United States
- ALDX United States
- Employees
- GSRT N/A
- ALDX N/A
- Industry
- GSRT
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- GSRT
- ALDX Health Care
- Exchange
- GSRT Nasdaq
- ALDX Nasdaq
- Market Cap
- GSRT 324.1M
- ALDX 270.7M
- IPO Year
- GSRT 2024
- ALDX 2014
- Fundamental
- Price
- GSRT $10.40
- ALDX $5.39
- Analyst Decision
- GSRT Strong Buy
- ALDX Strong Buy
- Analyst Count
- GSRT 1
- ALDX 2
- Target Price
- GSRT $19.00
- ALDX $9.50
- AVG Volume (30 Days)
- GSRT 890.4K
- ALDX 1.0M
- Earning Date
- GSRT 01-01-0001
- ALDX 08-07-2025
- Dividend Yield
- GSRT N/A
- ALDX N/A
- EPS Growth
- GSRT N/A
- ALDX N/A
- EPS
- GSRT 0.19
- ALDX N/A
- Revenue
- GSRT N/A
- ALDX N/A
- Revenue This Year
- GSRT N/A
- ALDX N/A
- Revenue Next Year
- GSRT N/A
- ALDX $29.89
- P/E Ratio
- GSRT $53.61
- ALDX N/A
- Revenue Growth
- GSRT N/A
- ALDX N/A
- 52 Week Low
- GSRT $9.86
- ALDX $1.14
- 52 Week High
- GSRT $11.49
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- GSRT N/A
- ALDX 64.33
- Support Level
- GSRT N/A
- ALDX $5.21
- Resistance Level
- GSRT N/A
- ALDX $5.35
- Average True Range (ATR)
- GSRT 0.00
- ALDX 0.29
- MACD
- GSRT 0.00
- ALDX -0.04
- Stochastic Oscillator
- GSRT 0.00
- ALDX 92.06
About GSRT GSR III Acquisition Corp. Ordinary Shares
GSR III Acquisition Corp is a blank check company.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.